Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

CAR-T therapy for autoimmune diseases: study withdrawn before starting

NCT ID NCT07152223

Disease control Sponsor: Guangzhou Bio-gene Technology Co., Ltd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study planned to test a new cell therapy (CD19-BCMA CAR-T) for people with connective tissue diseases like lupus and rheumatoid arthritis. The goal was to see if it is safe and can control the disease. However, the study was withdrawn before enrolling any participants, so no results are available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Aug 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

1 year to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Good compliance: The patient or their guardian understands and voluntarily signs the informed consent form, and it is expected that all documents, procedures, follow-up examinations and treatments stipulated in the study can be completed. 2. Previously diagnosed with one of the following diseases and meeting the corresponding latest international classification/diagnostic criteria : 1. Systemic lupus erythematosus (SLE); 2. Rheumatoid arthritis (RA); 3. Systemic scleroderma (SSc) ; 4. Sjogren's Syndrome (SS); 5. Polymyositis/dermatomyositis (PM/DM); 6. Mixed connective tissue disease (MCTD). 3. Researchers determine that the disease is in an active stage; 4. At least one autoantibody is positive in the serum or plasma during the screening period; 5. Insufficient response, intolerance or recurrence to at least one standard treatment; 6. The pregnancy test of the female subjects was negative, and the subjects agreed to take effective contraceptive measures throughout the trial period. 7. The patient's major tissues and organs are functioning well. Exclusion Criteria: 1. Intracranial hypertension or confusion; 2. Symptomatic heart failure or severe arrhythmia; 3. Respiratory failure; 4. Accompanied by other types of malignant tumors; 5. Diffuse vascular coagulation; 6. Serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value; 7. Sepsis or other difficult-to-control infections; 8. Uncontrollable diabetes; 9. Severe mental disorder; 10. Cranial magnetic resonance imaging (MRI) examination revealed obvious lesions in the intracranial cavity. 11. WHO physical status classification ≥ level 3; 12. Organ transplant recipients; 13. Pregnant and lactating women; 14. HIV+，HBV，HCV，EBV，CMV.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Connective tissue diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

connective tissue disorder mixed connective tissue disease rheumatoid arthritis Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Connective tissue diseases

Contacts and locations

Locations

  • Dongguan Taixin Hospital

    Dongguan, Guangdong, 523125, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.